Renowned heart failure cardiologist, Dr. William T. Abraham, makes this move to V-Wave after more than 16 years as Director of the Division of Cardiovascular Medicine at The Ohio State University. V-Wave Ltd., an early stage medtech company developing an implantable...
RELIEVE-HF is a global, randomized, controlled, double-blinded, 500 patient pivotal study to evaluate the safety and effectiveness of V-Wave’s novel therapy. V-Wave Ltd. announced today that it has enrolled the first patients in its global, 500 patient pivotal study...
$70M Series C financing led by Deerfield Management; V-Wave also announced upcoming launch of the RELIEVE-HF pivotal study. V-Wave Ltd., an Israel-based company that has developed a proprietary, minimally invasive implanted interatrial shunt device for treating...
Early Experience in Class III Heart Failure Patients was Favorable. V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF), announced today the results of its first human implants were published in The Lancet....
Funding to support further development of V-Wave’s Unidirectional Interatrial Shunt for the treatment of Heart Failure. V-Wave Ltd. announced that it has completed a Series B financing of $28M. New investors included Johnson & Johnson Innovation – JJDC Inc.,...
Recent Comments